Potential unmet need for gout diagnosis and treatment: capture―recapture analysis of a national administrative dataset

To estimate the degree of undercount of people diagnosed with gout in administrative datasets using capture-recapture methods. Hospitalization and drug dispensing claims (allopurinol or colchicine) data for all Aotearoa New Zealand were used to estimate the prevalence of gout in 2009 (n = 4 295 296)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatology (Oxford, England) England), 2012-10, Vol.51 (10), p.1820-1824
Hauptverfasser: JACKSON, Gary, WRIGHT, Craig, THORNLEY, Simon, TAYLOR, William J, KARU, Leanne Te, GOW, Peter J, ARROLL, Bruce, GRIBBEN, Barry, DALBETH, Nicola, WINNARD, Doone
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1824
container_issue 10
container_start_page 1820
container_title Rheumatology (Oxford, England)
container_volume 51
creator JACKSON, Gary
WRIGHT, Craig
THORNLEY, Simon
TAYLOR, William J
KARU, Leanne Te
GOW, Peter J
ARROLL, Bruce
GRIBBEN, Barry
DALBETH, Nicola
WINNARD, Doone
description To estimate the degree of undercount of people diagnosed with gout in administrative datasets using capture-recapture methods. Hospitalization and drug dispensing claims (allopurinol or colchicine) data for all Aotearoa New Zealand were used to estimate the prevalence of gout in 2009 (n = 4 295 296). As a comparison, we calculated gout prevalence using a large primary care dataset using general practitioner diagnosis and prescribing records (n = 555 313). For each of these datasets, we estimated the undercount through capture-recapture analysis using a Poisson regression model. A two-list model was used, which included covariates such as age, gender, ethnic groups and New Zealand deprivation quintiles. The crude prevalence of diagnosed gout in the Aotearoa New Zealand population aged ≥ 20 years was 3.75%. The covariate-adjusted capture-recapture estimate of those not recorded but likely to have gout was 0.92%, giving an overall estimated prevalence of 4.67% (95% CI 4.49, 4.90%) for the population aged ≥ 20 years. This amounts to 80% of people with gout being identified by the algorithm for the Aotearoa New Zealand data-that is being recorded in either lists of dispensing of allopurinol or colchicine or hospital discharge. After capture-recapture, gout prevalence for all males aged ≥ 20 years was 7.3% and in older (≥ 65 years) Māori and Pacific men was >30%. Capture-recapture analysis of administrative datasets provides a readily available method for estimating an aspect of unmet need in the population-in this instance potentially 20% of those with gout not being identified and treated specifically for this condition.
doi_str_mv 10.1093/rheumatology/kes147
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1074771338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1074771338</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-30a14579e0862aefa848f6c38ff0137ebb066aa6447ee3951ba2ae65899955b63</originalsourceid><addsrcrecordid>eNpN0M1O3DAQB3CrKuoC7RNUqnypxGVZO3bshBtC5UNaqRzgHE2S8daQ2FvbqdhbX4IX7JNgtMuW04xGv5mR_oR85eyUs1oswi-cRkh-8KvN4hEjl_oDOeRSFXMmRPFx3xdyRo5ifGCMlVxUn8isKHQhyro8JE-3PqFLFgY6uRETdYg9NT7QlZ8S7S2snI82UnA9TQEhjZmf0Q7WaQr47-9zwF2fCQybV-sNBeogWZ8nFPrROhtTyIM_SHtIEDF9JgcGhohfdvWY3F_-uLu4ni9_Xt1cnC_nnVAszQUDLktdI6tUAWigkpVRnaiMYVxobFumFICSUiOKuuQtZKbKqq7rsmyVOCYn27vr4H9PGFMz2tjhMIBDP8WGMy215kJUmYot7YKPMaBp1sGOEDYZNa-RN-8jb7aR561vuwdTO2K_33nLOIPvOwCxg8EEcJ2N_52SXNSVFi_THZI-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1074771338</pqid></control><display><type>article</type><title>Potential unmet need for gout diagnosis and treatment: capture―recapture analysis of a national administrative dataset</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>JACKSON, Gary ; WRIGHT, Craig ; THORNLEY, Simon ; TAYLOR, William J ; KARU, Leanne Te ; GOW, Peter J ; ARROLL, Bruce ; GRIBBEN, Barry ; DALBETH, Nicola ; WINNARD, Doone</creator><creatorcontrib>JACKSON, Gary ; WRIGHT, Craig ; THORNLEY, Simon ; TAYLOR, William J ; KARU, Leanne Te ; GOW, Peter J ; ARROLL, Bruce ; GRIBBEN, Barry ; DALBETH, Nicola ; WINNARD, Doone</creatorcontrib><description>To estimate the degree of undercount of people diagnosed with gout in administrative datasets using capture-recapture methods. Hospitalization and drug dispensing claims (allopurinol or colchicine) data for all Aotearoa New Zealand were used to estimate the prevalence of gout in 2009 (n = 4 295 296). As a comparison, we calculated gout prevalence using a large primary care dataset using general practitioner diagnosis and prescribing records (n = 555 313). For each of these datasets, we estimated the undercount through capture-recapture analysis using a Poisson regression model. A two-list model was used, which included covariates such as age, gender, ethnic groups and New Zealand deprivation quintiles. The crude prevalence of diagnosed gout in the Aotearoa New Zealand population aged ≥ 20 years was 3.75%. The covariate-adjusted capture-recapture estimate of those not recorded but likely to have gout was 0.92%, giving an overall estimated prevalence of 4.67% (95% CI 4.49, 4.90%) for the population aged ≥ 20 years. This amounts to 80% of people with gout being identified by the algorithm for the Aotearoa New Zealand data-that is being recorded in either lists of dispensing of allopurinol or colchicine or hospital discharge. After capture-recapture, gout prevalence for all males aged ≥ 20 years was 7.3% and in older (≥ 65 years) Māori and Pacific men was &gt;30%. Capture-recapture analysis of administrative datasets provides a readily available method for estimating an aspect of unmet need in the population-in this instance potentially 20% of those with gout not being identified and treated specifically for this condition.</description><identifier>ISSN: 1462-0324</identifier><identifier>ISSN: 1462-0332</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/kes147</identifier><identifier>PMID: 22723595</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Allopurinol - therapeutic use ; Biological and medical sciences ; Colchicine - therapeutic use ; Databases, Factual ; Diseases of the osteoarticular system ; Female ; Gout - diagnosis ; Gout - drug therapy ; Gout - epidemiology ; Gout Suppressants - therapeutic use ; Humans ; Inflammatory joint diseases ; Male ; Medical sciences ; Metabolic diseases ; Middle Aged ; Miscellaneous. Osteoarticular involvement in other diseases ; New Zealand - epidemiology ; Other metabolic disorders ; Prevalence ; Purines and pyrimidines (gout, hyperuricemia...) ; White People</subject><ispartof>Rheumatology (Oxford, England), 2012-10, Vol.51 (10), p.1820-1824</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-30a14579e0862aefa848f6c38ff0137ebb066aa6447ee3951ba2ae65899955b63</citedby><cites>FETCH-LOGICAL-c360t-30a14579e0862aefa848f6c38ff0137ebb066aa6447ee3951ba2ae65899955b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26413987$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22723595$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JACKSON, Gary</creatorcontrib><creatorcontrib>WRIGHT, Craig</creatorcontrib><creatorcontrib>THORNLEY, Simon</creatorcontrib><creatorcontrib>TAYLOR, William J</creatorcontrib><creatorcontrib>KARU, Leanne Te</creatorcontrib><creatorcontrib>GOW, Peter J</creatorcontrib><creatorcontrib>ARROLL, Bruce</creatorcontrib><creatorcontrib>GRIBBEN, Barry</creatorcontrib><creatorcontrib>DALBETH, Nicola</creatorcontrib><creatorcontrib>WINNARD, Doone</creatorcontrib><title>Potential unmet need for gout diagnosis and treatment: capture―recapture analysis of a national administrative dataset</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>To estimate the degree of undercount of people diagnosed with gout in administrative datasets using capture-recapture methods. Hospitalization and drug dispensing claims (allopurinol or colchicine) data for all Aotearoa New Zealand were used to estimate the prevalence of gout in 2009 (n = 4 295 296). As a comparison, we calculated gout prevalence using a large primary care dataset using general practitioner diagnosis and prescribing records (n = 555 313). For each of these datasets, we estimated the undercount through capture-recapture analysis using a Poisson regression model. A two-list model was used, which included covariates such as age, gender, ethnic groups and New Zealand deprivation quintiles. The crude prevalence of diagnosed gout in the Aotearoa New Zealand population aged ≥ 20 years was 3.75%. The covariate-adjusted capture-recapture estimate of those not recorded but likely to have gout was 0.92%, giving an overall estimated prevalence of 4.67% (95% CI 4.49, 4.90%) for the population aged ≥ 20 years. This amounts to 80% of people with gout being identified by the algorithm for the Aotearoa New Zealand data-that is being recorded in either lists of dispensing of allopurinol or colchicine or hospital discharge. After capture-recapture, gout prevalence for all males aged ≥ 20 years was 7.3% and in older (≥ 65 years) Māori and Pacific men was &gt;30%. Capture-recapture analysis of administrative datasets provides a readily available method for estimating an aspect of unmet need in the population-in this instance potentially 20% of those with gout not being identified and treated specifically for this condition.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Allopurinol - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Colchicine - therapeutic use</subject><subject>Databases, Factual</subject><subject>Diseases of the osteoarticular system</subject><subject>Female</subject><subject>Gout - diagnosis</subject><subject>Gout - drug therapy</subject><subject>Gout - epidemiology</subject><subject>Gout Suppressants - therapeutic use</subject><subject>Humans</subject><subject>Inflammatory joint diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Miscellaneous. Osteoarticular involvement in other diseases</subject><subject>New Zealand - epidemiology</subject><subject>Other metabolic disorders</subject><subject>Prevalence</subject><subject>Purines and pyrimidines (gout, hyperuricemia...)</subject><subject>White People</subject><issn>1462-0324</issn><issn>1462-0332</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpN0M1O3DAQB3CrKuoC7RNUqnypxGVZO3bshBtC5UNaqRzgHE2S8daQ2FvbqdhbX4IX7JNgtMuW04xGv5mR_oR85eyUs1oswi-cRkh-8KvN4hEjl_oDOeRSFXMmRPFx3xdyRo5ifGCMlVxUn8isKHQhyro8JE-3PqFLFgY6uRETdYg9NT7QlZ8S7S2snI82UnA9TQEhjZmf0Q7WaQr47-9zwF2fCQybV-sNBeogWZ8nFPrROhtTyIM_SHtIEDF9JgcGhohfdvWY3F_-uLu4ni9_Xt1cnC_nnVAszQUDLktdI6tUAWigkpVRnaiMYVxobFumFICSUiOKuuQtZKbKqq7rsmyVOCYn27vr4H9PGFMz2tjhMIBDP8WGMy215kJUmYot7YKPMaBp1sGOEDYZNa-RN-8jb7aR561vuwdTO2K_33nLOIPvOwCxg8EEcJ2N_52SXNSVFi_THZI-</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>JACKSON, Gary</creator><creator>WRIGHT, Craig</creator><creator>THORNLEY, Simon</creator><creator>TAYLOR, William J</creator><creator>KARU, Leanne Te</creator><creator>GOW, Peter J</creator><creator>ARROLL, Bruce</creator><creator>GRIBBEN, Barry</creator><creator>DALBETH, Nicola</creator><creator>WINNARD, Doone</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121001</creationdate><title>Potential unmet need for gout diagnosis and treatment: capture―recapture analysis of a national administrative dataset</title><author>JACKSON, Gary ; WRIGHT, Craig ; THORNLEY, Simon ; TAYLOR, William J ; KARU, Leanne Te ; GOW, Peter J ; ARROLL, Bruce ; GRIBBEN, Barry ; DALBETH, Nicola ; WINNARD, Doone</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-30a14579e0862aefa848f6c38ff0137ebb066aa6447ee3951ba2ae65899955b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Allopurinol - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Colchicine - therapeutic use</topic><topic>Databases, Factual</topic><topic>Diseases of the osteoarticular system</topic><topic>Female</topic><topic>Gout - diagnosis</topic><topic>Gout - drug therapy</topic><topic>Gout - epidemiology</topic><topic>Gout Suppressants - therapeutic use</topic><topic>Humans</topic><topic>Inflammatory joint diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Miscellaneous. Osteoarticular involvement in other diseases</topic><topic>New Zealand - epidemiology</topic><topic>Other metabolic disorders</topic><topic>Prevalence</topic><topic>Purines and pyrimidines (gout, hyperuricemia...)</topic><topic>White People</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JACKSON, Gary</creatorcontrib><creatorcontrib>WRIGHT, Craig</creatorcontrib><creatorcontrib>THORNLEY, Simon</creatorcontrib><creatorcontrib>TAYLOR, William J</creatorcontrib><creatorcontrib>KARU, Leanne Te</creatorcontrib><creatorcontrib>GOW, Peter J</creatorcontrib><creatorcontrib>ARROLL, Bruce</creatorcontrib><creatorcontrib>GRIBBEN, Barry</creatorcontrib><creatorcontrib>DALBETH, Nicola</creatorcontrib><creatorcontrib>WINNARD, Doone</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JACKSON, Gary</au><au>WRIGHT, Craig</au><au>THORNLEY, Simon</au><au>TAYLOR, William J</au><au>KARU, Leanne Te</au><au>GOW, Peter J</au><au>ARROLL, Bruce</au><au>GRIBBEN, Barry</au><au>DALBETH, Nicola</au><au>WINNARD, Doone</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential unmet need for gout diagnosis and treatment: capture―recapture analysis of a national administrative dataset</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>51</volume><issue>10</issue><spage>1820</spage><epage>1824</epage><pages>1820-1824</pages><issn>1462-0324</issn><issn>1462-0332</issn><eissn>1462-0332</eissn><abstract>To estimate the degree of undercount of people diagnosed with gout in administrative datasets using capture-recapture methods. Hospitalization and drug dispensing claims (allopurinol or colchicine) data for all Aotearoa New Zealand were used to estimate the prevalence of gout in 2009 (n = 4 295 296). As a comparison, we calculated gout prevalence using a large primary care dataset using general practitioner diagnosis and prescribing records (n = 555 313). For each of these datasets, we estimated the undercount through capture-recapture analysis using a Poisson regression model. A two-list model was used, which included covariates such as age, gender, ethnic groups and New Zealand deprivation quintiles. The crude prevalence of diagnosed gout in the Aotearoa New Zealand population aged ≥ 20 years was 3.75%. The covariate-adjusted capture-recapture estimate of those not recorded but likely to have gout was 0.92%, giving an overall estimated prevalence of 4.67% (95% CI 4.49, 4.90%) for the population aged ≥ 20 years. This amounts to 80% of people with gout being identified by the algorithm for the Aotearoa New Zealand data-that is being recorded in either lists of dispensing of allopurinol or colchicine or hospital discharge. After capture-recapture, gout prevalence for all males aged ≥ 20 years was 7.3% and in older (≥ 65 years) Māori and Pacific men was &gt;30%. Capture-recapture analysis of administrative datasets provides a readily available method for estimating an aspect of unmet need in the population-in this instance potentially 20% of those with gout not being identified and treated specifically for this condition.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>22723595</pmid><doi>10.1093/rheumatology/kes147</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1462-0324
ispartof Rheumatology (Oxford, England), 2012-10, Vol.51 (10), p.1820-1824
issn 1462-0324
1462-0332
1462-0332
language eng
recordid cdi_proquest_miscellaneous_1074771338
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection
subjects Adult
Aged
Aged, 80 and over
Allopurinol - therapeutic use
Biological and medical sciences
Colchicine - therapeutic use
Databases, Factual
Diseases of the osteoarticular system
Female
Gout - diagnosis
Gout - drug therapy
Gout - epidemiology
Gout Suppressants - therapeutic use
Humans
Inflammatory joint diseases
Male
Medical sciences
Metabolic diseases
Middle Aged
Miscellaneous. Osteoarticular involvement in other diseases
New Zealand - epidemiology
Other metabolic disorders
Prevalence
Purines and pyrimidines (gout, hyperuricemia...)
White People
title Potential unmet need for gout diagnosis and treatment: capture―recapture analysis of a national administrative dataset
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T13%3A16%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20unmet%20need%20for%20gout%20diagnosis%20and%20treatment:%20capture%E2%80%95recapture%20analysis%20of%20a%20national%20administrative%20dataset&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=JACKSON,%20Gary&rft.date=2012-10-01&rft.volume=51&rft.issue=10&rft.spage=1820&rft.epage=1824&rft.pages=1820-1824&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/kes147&rft_dat=%3Cproquest_cross%3E1074771338%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1074771338&rft_id=info:pmid/22723595&rfr_iscdi=true